DaCapo Brainscience, a biotechnology company leveraging a proprietary discovery platform to develop small-molecule therapies for neurodegenerative diseases, today announced significant leadership changes aimed at advancing its pipeline toward clinical trials. Leslie Williams has been appointed President and Chief Executive Officer, Mridul Mehta, PhD, has been named Chief Technology Officer, and Warren Hirst, PhD, has been promoted to Chief Scientific Officer.
The appointments come as the company transitions from early discovery to clinical-stage drug development. Williams, a biotech veteran, brings extensive experience in leading companies through regulatory and clinical milestones. Her appointment is expected to guide DaCapo's efforts to identify and develop therapies that can slow or halt the progression of neurodegenerative diseases, with an initial focus on Parkinson's disease.
Mridul Mehta, PhD, joins as Chief Technology Officer, where he will oversee the company's proprietary discovery platform, which combines advanced data analysis with human-based laboratory models to identify new disease pathways. Warren Hirst, PhD, previously serving in a senior scientific role, has been promoted to Chief Scientific Officer, where he will lead research and development strategies.
DaCapo's platform aims to recapitulate human biology in vitro, enabling the identification of small-molecule therapies that target disease mechanisms. The company believes this approach could lead to treatments that slow or stop disease progression, addressing a critical unmet need in neurodegenerative conditions such as Parkinson's disease.
The leadership restructuring is part of DaCapo's broader strategy to strengthen its executive team as it prepares for the next phase of growth. The company has not disclosed specific timelines for clinical trials but has indicated that the new leadership will accelerate the development of its pipeline.
For more details on the announcement, including downloadable images and bios, visit DaCapo Brainscience.
